BR0108442A - Mutantes-ehv gm-negativos - Google Patents

Mutantes-ehv gm-negativos

Info

Publication number
BR0108442A
BR0108442A BR0108442-9A BR0108442A BR0108442A BR 0108442 A BR0108442 A BR 0108442A BR 0108442 A BR0108442 A BR 0108442A BR 0108442 A BR0108442 A BR 0108442A
Authority
BR
Brazil
Prior art keywords
ehv
methods
viruses
nucleic acids
wild type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
BR0108442-9A
Other languages
English (en)
Inventor
Christian Seyboldt
Nikolaus Osterrieder
Knut Elbers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Vetmedica de C V SA
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Vetmedica de C V SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica GmbH, Boehringer Ingelheim Vetmedica de C V SA filed Critical Boehringer Ingelheim Vetmedica GmbH
Publication of BR0108442A publication Critical patent/BR0108442A/pt
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/27—Equine rhinopneumonitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"MUTANTES-EHV gM-NEGATIVOS". A presente invenção refere-se ao Vírus do Herpes de Eq³ino (EHV) em que a proteína gM está essencialmente ausente ou modificada e não-funcional com relação à sua capacidade imunomodulatória. Outros aspectos da invenção referem-se a ácidos nucléicos que codificam os referidos vírus, composições farmacêuticas compreendendo esses vírus ou ácidos nucléicos e usos dos mesmos. A invenção também refere-se a métodos para melhora da resposta imune induzida por uma vacina de EHV contra infecções pelo EHV do tipo silvestre, métodos para a profilaxia e tratamento de infecções pelo EHV e métodos para distinguir animais infectados pelo EHV do tipo silvestre de animais tratados com os EHV de acordo com a invenção.
BR0108442-9A 2000-02-17 2001-02-15 Mutantes-ehv gm-negativos Pending BR0108442A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00103241A EP1129722A1 (en) 2000-02-17 2000-02-17 gM-negative EHV-mutants
PCT/EP2001/001672 WO2001060403A1 (en) 2000-02-17 2001-02-15 Gm-negative ehv-mutants

Publications (1)

Publication Number Publication Date
BR0108442A true BR0108442A (pt) 2003-03-25

Family

ID=8167872

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108442-9A Pending BR0108442A (pt) 2000-02-17 2001-02-15 Mutantes-ehv gm-negativos

Country Status (24)

Country Link
US (3) US6703231B2 (pt)
EP (2) EP1129722A1 (pt)
JP (1) JP5177927B2 (pt)
KR (1) KR100845192B1 (pt)
CN (2) CN100378216C (pt)
AR (1) AR027443A1 (pt)
AT (1) ATE422363T1 (pt)
AU (2) AU2001248313B2 (pt)
BR (1) BR0108442A (pt)
CA (1) CA2399846C (pt)
CO (1) CO5280143A1 (pt)
CY (1) CY1109023T1 (pt)
CZ (1) CZ303657B6 (pt)
DE (1) DE60137621D1 (pt)
DK (1) DK1259258T3 (pt)
ES (1) ES2322236T3 (pt)
HK (1) HK1052462A1 (pt)
HU (1) HU228217B1 (pt)
MX (1) MXPA02008009A (pt)
NZ (1) NZ521365A (pt)
PL (1) PL210441B1 (pt)
PT (1) PT1259258E (pt)
UY (1) UY26588A1 (pt)
WO (1) WO2001060403A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1129722A1 (en) * 2000-02-17 2001-09-05 Boehringer Ingelheim Vetmedica Gmbh gM-negative EHV-mutants
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
AR040601A1 (es) 2002-07-19 2005-04-13 Boehringer Ingelheim Vetmed Mutantes ehv negativos de gm sin elementos heterologos
DE10233064A1 (de) * 2002-07-19 2004-02-05 Boehringer Ingelheim Vetmedica Gmbh gM-negative EHV-Mutanten ohne heterologe Elemente
EP1394258A1 (en) * 2002-08-30 2004-03-03 Geneart GmbH Non-human herpesviruses as vectors
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731188A (en) * 1986-11-20 1998-03-24 Syntro Corporation Recombinant equine herpesviruses
GB9014950D0 (en) * 1990-07-06 1990-08-29 Univ Glasgow Ehv-4 glycoprotein vaccine
US5674735A (en) * 1990-07-06 1997-10-07 University Court Of The University Of Glasgow DNA encoding the EHV-4 gH or gC glycoprotein
DE4110962A1 (de) * 1991-04-05 1992-10-08 Bayer Ag Equine herpesviren (ehv), die fremd-dna enthalten, verfahren zu ihrer herstellung und ihre verwendung in impfstoffen
US6193983B1 (en) * 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
EP0655072B1 (en) * 1992-06-01 2004-02-11 The University Of Melbourne Immunological method for the detection of antibodies to equine herpesvirus type 1 and 4 glycoprotein G
US5853715A (en) * 1996-08-16 1998-12-29 Bayer Corporation Cross-protective equine herpesvirus preparations and method of making and using the same
GB9625968D0 (en) 1996-12-13 1997-01-29 Univ Glasgow Vaccine
GB9626029D0 (en) * 1996-12-14 1997-01-29 Univ Leeds EVH-1 vectors
WO2000008165A1 (en) 1998-07-31 2000-02-17 Akzo Nobel N.V. Attenuated equine herpesvirus
HUP0202738A3 (en) 1999-09-10 2003-12-29 Akzo Nobel Nv Equine herpes virus temperature sensitive mutant and live vaccine thereof
EP1129722A1 (en) * 2000-02-17 2001-09-05 Boehringer Ingelheim Vetmedica Gmbh gM-negative EHV-mutants
NZ523772A (en) 2000-07-27 2004-06-25 Res Corp Technologies Inc Vaccines for equine herpesvirus type-1: viruses harboring mutations within the immediate early gene
AR040601A1 (es) * 2002-07-19 2005-04-13 Boehringer Ingelheim Vetmed Mutantes ehv negativos de gm sin elementos heterologos
DE10233064A1 (de) 2002-07-19 2004-02-05 Boehringer Ingelheim Vetmedica Gmbh gM-negative EHV-Mutanten ohne heterologe Elemente

Also Published As

Publication number Publication date
HK1052462A1 (zh) 2003-09-19
US20030198650A1 (en) 2003-10-23
MXPA02008009A (es) 2003-01-28
AR027443A1 (es) 2003-03-26
US8017317B2 (en) 2011-09-13
PL357019A1 (en) 2004-07-12
US6703231B2 (en) 2004-03-09
ATE422363T1 (de) 2009-02-15
JP5177927B2 (ja) 2013-04-10
CZ303657B6 (cs) 2013-02-06
CA2399846A1 (en) 2001-08-23
CA2399846C (en) 2011-06-14
HUP0204446A2 (en) 2003-05-28
PL210441B1 (pl) 2012-01-31
AU4831301A (en) 2001-08-27
CN1400907A (zh) 2003-03-05
DE60137621D1 (de) 2009-03-26
AU2001248313B2 (en) 2006-03-02
KR20030032914A (ko) 2003-04-26
US20040063095A1 (en) 2004-04-01
EP1259258A1 (en) 2002-11-27
EP1129722A1 (en) 2001-09-05
CN100378216C (zh) 2008-04-02
HU228217B1 (en) 2013-02-28
JP2003522542A (ja) 2003-07-29
UY26588A1 (es) 2001-09-28
ES2322236T3 (es) 2009-06-18
EP1259258B1 (en) 2009-02-11
DK1259258T3 (da) 2009-06-02
CN101230336A (zh) 2008-07-30
WO2001060403A1 (en) 2001-08-23
PT1259258E (pt) 2009-03-18
HUP0204446A3 (en) 2010-01-28
US7309598B2 (en) 2007-12-18
CZ20022809A3 (cs) 2003-01-15
NZ521365A (en) 2004-07-30
CO5280143A1 (es) 2003-05-30
KR100845192B1 (ko) 2008-07-10
US20080160046A1 (en) 2008-07-03
CY1109023T1 (el) 2014-07-02

Similar Documents

Publication Publication Date Title
BR0111366A (pt) Vacina de poxvìrus recombinante do vìrus da sìndrome respiratória e reprodutiva de porcino (prrsv)
WO2000077216A3 (en) Porcine circovirus vaccine in recombinant poxvirus
BR9908615A (pt) Proteìnas codificadas por ácidos polinucléicos de vìrus da sìndrome reprodutiva e respiratória de suìnos (prrsv)
GR3035458T3 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
DE69536039D1 (de) Wirtszelle enthaltend ein rekombinantes Virus, welches ein Antigen exprimiert und ein rekombinantes Virus, welches ein immunstimulatorisches Molekül exprimiert
PT93393A (pt) Processo para a preparacao de vacinas e de agentes de diagnostico que contem regioes imunogenicas de proteina e7do virus do papiloma humano do tipo 16 ou anticorpos suscitados contra estas regioes
BR9201848A (pt) Processo para a preparacao de particuals de virus para vacinas,vacina,e,processo para tratamento ou profilaxia de uma infeccao viral em um mamifero com necessidade dos mesmos
RU93058614A (ru) Мутант вируса герпеса, композиции, диагностические наборы, способы определения инфекции
DE69637914D1 (de) Impstoff gegen den für atemwegs- und reproduktionserkrankungen beim schwein verantwortlichen virus
ATE347375T1 (de) Rekombinante hunde-herpesviren
DK0437604T3 (da) Rekombinant poxvirus- og streptokok M-proteinvaccine
EA200100302A1 (ru) Способы и композиции для протективной и терапевтической генетической иммунизации
BR0316291A (pt) Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv
BR0108442A (pt) Mutantes-ehv gm-negativos
PT652287E (pt) Vectores de poxvirus e sua utilizacao contra doenca pelo virus da peritonite infecciosa felina
BR0206995A (pt) Tratamento do vìrus da hepatite b
FR2781158B1 (fr) Nouvelles proteines modifiees immunogenes non immunosuppressives, leur procede de preparation et leurs applications
DE3751772T2 (de) Impfstoff zur behandlung von hsv
YU12991A (sh) Rekombinantne vakcine protiv kokcidioze-5-7 eimeria površinski antigen
BR9707400A (pt) Vacinas contra produto do gene 63 de vìrus varicella zoster.
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren
BR9603227A (pt) Vírus ndv da cepa c2 vacina para uso na proteção de aves omésticas contra doença de newcastle (nd) processos para a preparação de vírus para preparação de uma vacina e para controlar doença de newcastle em aves domésticas
DE69203950T2 (de) Rekombinanter Impfstoff gegen Marek's Krankheit.
DE69417717T2 (de) Impstoff zum Schutze von Pferden gegen Pferdeherpesvirus-Infektionen
BR0110791A (pt) Composição, métodos para induzir uma resposta imune em um indivìduo contra um imunogene, para modular o sistema imune de um indivìduo e para imunizar um indivìduo contra um patógeno, vacina recombinante, e patógeno atenuado vivo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 37, 8O, 13 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 15A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2363 DE 19-04-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.